Assertio Board Unanimously Recommends $23.50/Share All-Cash Tender Offer by Zydus
ASRT has more than doubled off its 52-week low of $8.61.
Summary
Assertio Holdings' Board of Directors unanimously recommends shareholders accept Zydus Worldwide DMCC's all-cash tender offer of $23.50 per share, which provides immediate liquidity and a significant premium, following the termination of a prior merger agreement with Garda Therapeutics.
Key Events · M&A and Partnerships · ASRT
-
Board Recommends Tender Offer
Assertio's Board of Directors unanimously recommends shareholders accept the $23.50 per share all-cash tender offer from Zydus Worldwide DMCC.
-
Significant Acquisition Premium
The $23.50 offer price represents a 75.8% premium to the unaffected market price of $13.37 as of March 20, 2026, and a 7.8% premium to the previously amended Garda offer of $21.80.
-
Termination of Prior Merger Agreement
The company terminated its merger agreement with Garda Therapeutics to accept Zydus's superior offer, which offers greater certainty of closing with no financing contingencies and a full guarantee.
-
Strategic Rationale for Sale
The Board cited dependence on a single product (Rolvedon) with a limited commercial lifecycle, lack of internal R&D, projected decline in revenue and Adjusted EBITDA, and capital structure considerations as key drivers for pursuing a whole-company sale.
Analysis · ASRT · Life Sciences
This SC 14D9 filing details Assertio's Board of Directors' unanimous recommendation for shareholders to accept Zydus Worldwide DMCC's all-cash tender offer of $23.50 per share. This definitive agreement provides a substantial premium and immediate liquidity for shareholders, addressing the company's strategic challenges, including its reliance on a single product with a limited lifecycle and declining financial projections. The Board explicitly chose this offer over a prior, lower bid from Garda Therapeutics, citing superior value and greater certainty of closing due to Zydus's lack of financing contingencies and a full guarantee. The offer price represents a significant premium to the unaffected market price and the previously amended Garda offer. The company's stock is currently trading near its 52-week high, reflecting the positive market reaction to the acquisition news. The transaction will result in Assertio ceasing to be a publicly traded company.
At the time of this filing, ASRT was trading at $23.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $150.7M. The 52-week trading range was $8.61 to $23.36. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.